Radiation Therapy With Capecitabine in Rectal Cancer
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study will use an experimental combination of treatment with the drug Capecitabine and
radiation therapy prior to an operation for removal of the patient's tumor. The drug
Capecitabine is an oral form of a drug called 5-FU which has been widely used to treat rectal
cancer.
This is a phase II clinical trial, which means that the physician will be studying the
reactions of the patient's body and tumor to treatment with Capecitabine and radiation
therapy. The purpose of this study is to see if the tumor responds to this treatment and to
determine how long the response lasts. The study also will see what kind of side effects this
experimental treatment causes and see how often these side effects occur.
Preliminary human studies using Capecitabine and radiation therapy have produced encouraging
results with acceptable side effects.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center